Recommendation of the President – Braftovi (encorafenib)
On 21 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 51/2026 on the inclusion of the medicinal product Braftovi (encorafenib) in the reimbursement program B.4. “Treatment of patients with colorectal cancer (ICD-10: C18-C20)”